Key result
High IL-6 amplifies elevated Lp(a)-associated incident CAD risk by ~43%.
Why the study?
Do inflammatory biomarkers modify the risk of incident CAD and AS associated with elevated Lp(a) in a primary prevention population?
Cohort (n=43,512)
Do inflammatory biomarkers modify the risk of incident CAD and AS associated with elevated Lp(a) in a primary prevention population?
Hazard Ratio: 1.43 (95% CI 1.25–1.63)
p-value: p=.008 for interaction
In a primary prevention cohort, higher IL-6 levels significantly amplified the risk of incident CAD associated with elevated Lp(a), suggesting inflammation modifies Lp(a)-related cardiovascular risk.
Importance: Clinical heterogeneity exists among individuals with elevated lipoprotein(a) [Lp(a)] levels. Prior studies suggest that low-grade inflammation may modify this risk, but results remain conflicting. Objective: To test the hypothesis that inflammatory biomarkers may modify Lp(a)-associated risk for coronary artery disease (CAD) and aortic valve stenosis (AS) in a primary prevention population. Design, Setting, and Participants: Recruitment occurred between March 2006 through October 2010 among a population-based cohort of UK adults. UK Biobank participants without prevalent CAD or AS who underwent plasma proteomic profiling at study entry were eligible for inclusion. Data were analyzed from June 2025 through April 2026. Exposures: Lp(a) levels (<125 nmol/L vs ≥125 nmol/L) and inflammatory biomarkers interleukin 1β (IL-1β), IL-18, IL-6, and the neutrophil to lymphocyte ratio (NLR). Main Outcomes and Measures: The primary outcome was the risk of incident CAD. The secondary outcome was the risk of incident AS. Results: Among 43 512 UK Biobank participants, 6975 (16.0%) had Lp(a) levels of 125 nmol/L or higher, 24 079 (55.3%) were female, and overall mean (SD) age was 56.5 (8.2) years. Median (Q1-Q3) follow-up was 13.5 (12.7-14.3) years for incident CAD and 13.6 (12.9-14.4) years for incident AS. Multivariable-adjusted Cox proportional hazards models tested the interaction between Lp(a) levels and each inflammatory biomarker in relation to the primary and secondary outcomes. Among inflammatory biomarkers tested, IL-6 demonstrated the strongest association with both incident CAD and AS. IL-6 levels modified Lp(a)-associated risk for incident CAD (hazard ratio [HR] for Lp(a) ≥125 nmol/L vs <125 nmol/L in quartile 4 of IL-6: 1.43; 95% CI, 1.25-1.63 vs in quartile 1 of IL-6: HR, 1.09; 95% CI, 0.85-1.38; P for interaction = .008). The interaction between Lp(a) and the NLR (P for interaction = .02) was suggestive but not significant after adjustment for multiple testing. No inflammatory biomarkers modified Lp(a)-associated risk for AS. Conclusions and Relevance: In this primary prevention cohort study, Lp(a)-associated risk for incident CAD was modified by IL-6, with lower associated risk observed in the setting of lower inflammatory biomarker levels. These findings identify IL-6 as a biomarker of inflammatory risk that may modify Lp(a)-associated CAD risk.
No takes yet. Share an insight, caveat, or question.
Mohammadnia et al. (2026) conducted a cohort in Primary prevention of coronary artery disease and aortic valve stenosis (n=43,512). Elevated Lp(a) levels (≥125 nmol/L) and IL-6 levels vs. Lp(a) <125 nmol/L and lower IL-6 levels was evaluated on Incident CAD (HR 1.43, 95% CI 1.25-1.63, p=.008 for interaction). Elevated Lp(a) associated risk for incident CAD was significantly modified by IL-6 levels, with higher risk in the highest IL-6 quartile (HR 1.43; 95% CI 1.25-1.63; P=0.008 for interaction).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: